预约演示

更新于：2025-06-05

Atezolizumab

阿替利珠单抗

更新于：2025-06-05

概要

基本信息

药物类型

单克隆抗体

别名

Anti-PDL-1-Genentech/Roche、Atezolizumab (Genetical Recombination)、Atezolizumab (genetical recombination) (JAN)

+ [11]

靶点

PDL1

作用方式

抑制剂

作用机制

PDL1抑制剂(程序性死亡配体1抑制剂)

治疗领域

肿瘤消化系统疾病呼吸系统疾病+ [11]

在研适应症

晚期非小细胞肺癌乳腺癌肺泡软组织肉瘤+ [169]

非在研适应症

急性髓性白血病大肠腺癌晚期胆管癌+ [77]

原研机构

Genentech, Inc.Universitair Medisch Centrum Groningen

在研机构

Roche Registration GmbHHoffmann-La Roche, Inc.

罗氏（中国）投资有限公司

+ [27]

非在研机构

Kymab Ltd.

Sanofi

Basilea Pharmaceutica AG

+ [7]

权益机构

NeoImmuneTech, Inc.

Harpoon Therapeutics, Inc.Novocure, Inc.

+ [25]

最高研发阶段批准上市

首次获批日期

美国 (2016-05-18),

尿路上皮癌

最高研发阶段(中国)批准上市

特殊审评突破性疗法 (美国)、快速通道 (美国)、加速批准 (美国)、孤儿药 (美国)、附条件批准 (中国)、孤儿药 (澳大利亚)、优先审评 (澳大利亚)、优先审评 (中国)

登录后查看时间轴

结构/序列

Sequence Code 122091L

来源: *****

Sequence Code 4720027H

来源: *****

关联

854

项与阿替利珠单抗相关的临床试验

NCT06719973

/ Not yet recruiting临床1期

An Open Label, Multicenter, Phase 1 Study of the PARP1 Inhibitor M9466 in Combination With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic, and preliminary clinical activity of M9466 in combinations with carboplatin in advanced or metastatic refractory solid tumor and with the standard of care (carboplatin, etoposide, and atezolizumab) in treatment-naïve ES-SCLC. The results will support any investigation of carboplatin-based combination anticancer treatments with M9466 as well as the selection of a RP2D of M9466 in combination with carboplatin, etoposide, and atezolizumab for a subsequent ES-SCLC study.

开始日期2025-07-01

申办/合作机构

EMD Serono Research & Development Institute, Inc.

[+1]

NCT06294548

/ Not yet recruiting临床1/2期IIT

A Phase Ib/II, Dose Escalation and Dose Expansion Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma (HCC)

This is a phase Ib/II, dose escalation and dose expansion study of valemetostat (DS-3201) with atezolizumab and bevacizumab in patients advanced Hepatocellular carcinoma (HCC) who did not receive prior systemic therapy for advanced HCC.

开始日期2025-06-30

申办/合作机构

The University of Alabama at Birmingham

NCT05870800

/ Recruiting临床2期IIT

Phase II Open-label Trial of Neoadjuvant Immunotherapy (Atezolizumab) in Combination With CAPOX for Resectable Non-metastatic Proficient Mismatch Repair (pMMR) Colon CancER: NICER Study

This is a Phase II open-label trial of neoadjuvant immunochemotherapy with Atezolizumab and CAPOX followed by surgery and potentially adjuvant chemotherapy for patients with localized resectable pMMR adenocarcinoma of the colon with a target accrual of 28 patients. The investigators will explore if appropriately timed neoadjuvant CAPOX with anti-PD-L1 mAb (Atezolizumab) can be administered safely and feasibly, and that this combination will lead to improved clinical response associated with enhanced numbers of immune cells in surgically resected colon tumors. Patients will receive 4 cycles of atezolizumab in combination with 4 cycles of CAPOX (atezolizumab will be administered prior to chemotherapy) before standard of care surgical resection. Following surgery, patients still considered to be at high-risk of recurrence (per SOC guidelines) will receive further adjuvant chemotherapy (mFOLFOX6 or CAPOX), based on the discretion of the treating oncologist/investigator. Circulating tumor DNA (ctDNA) dynamic change status will be analyzed through collection of blood samples throughout different stages of the patient's neoadjuvant treatment regimen (baseline, pre-neoadjuvant therapy, mid-neoadjuvant, post-neoadjuvant therapy, and during postoperative period) as a marker of early read on efficacy.
The end of the study for each patient enrolled will be at the 6 month postoperative visit.
On Study Protocol: Patients will be followed up for an efficacy follow-up phase during the first 6 months after surgery (week 2 & months 3, 6 visits). All assessments beyond the 6 month visit will be performed under standard of care surveillance office visits.
Off Study Protocol: Thereafter they will enter a survival follow-up phase per standard of care protocols. Patients will be seen every 6 months starting at month 12 until month 36. All collection of research-specific assessments including whole blood, stool collection and quality of life questionnaires will be optional beyond the 6 month postop visit (months 12-36).

开始日期2025-06-15

申办/合作机构

Baylor College of Medicine

[+1]

100 项与阿替利珠单抗相关的临床结果

登录后查看更多信息

100 项与阿替利珠单抗相关的转化医学

登录后查看更多信息

100 项与阿替利珠单抗相关的专利（医药）

登录后查看更多信息

4,539

项与阿替利珠单抗相关的文献（医药）

2025-12-01·CANCER CHEMOTHERAPY AND PHARMACOLOGY

Potential role of endothelial dysfunction in hypertension and proteinuria in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab: a pilot prospective observational study

Article

作者: Kudo, Kenzo ; Nihei, Satoru ; Oikawa, Takayoshi ; Saito, Kazuki ; Asaka, Junichi ; Ikeda, Tatsuki ; Asahi, Koichi

PURPOSE:

Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), is the first-line treatment for patients with unresectable hepatocellular carcinoma (HCC). Its inhibition of VEGF signaling may lead to proteinuria due to endothelial dysfunction but the association between endothelial function and clinical outcomes has not been established. This study aimed to investigate vascular endothelial function in patients with HCC receiving atezolizumab plus bevacizumab, and to assess the correlation between reactive hyperemia index (RHI) and adverse renal outcomes.

METHODS:

This pilot prospective observational study included 20 patients with HCC who received atezolizumab plus bevacizumab. We used reactive hyperemia-peripheral arterial tonometry (RH-PAT) and evaluated vascular endothelial function on the basis of RHI. RHI, blood pressure, and proteinuria were recorded at baseline and at 3 and 6 months after initiation of atezolizumab plus bevacizumab treatment. Statistical analyses were performed to investigate the relationship of RHI to blood pressure and proteinuria.

RESULTS:

Following initiation of atezolizumab plus bevacizumab treatment, systolic blood pressure and urine protein-creatinine ratio increased significantly, and RHI decreased. Patients with borderline or low baseline RHI had a higher incidence of grade ≥ 2 proteinuria than those with normal baseline RHI but not hypertension. A significant inverse correlation was found between RHI and urine protein-creatinine ratio.

CONCLUSION:

Bevacizumab administration may cause endothelial dysfunction in patients with HCC. The vascular endothelial function status before and during atezolizumab plus bevacizumab treatment is associated with the risk of bevacizumab-induced proteinuria.

2025-08-01·WATER RESEARCH

Effects of microplastics on atrazine removal in constructed wetlands: Insight into the response characteristics of microorganisms, enzyme activity, and functional genes

Article

作者: Hu, Zhen ; Wu, Haiming ; Kong, Qiaoping ; Chen, Bo ; Wang, Longmian ; Yuan, Qianyin ; Lian, Jianjun

Constructed wetlands (CWs) technology has been widely used to treat agricultural non-point source pollution. However, knowledge about the impact mechanism and distribution characteristics of microplastics (MPs) on pesticide treatment in CWs is limited. This study employed atrazine (ATZ), a representative pesticide, as a model contaminant, to systematically investigate the impacts of polyethylene microplastics (PE MPs) on the removal of ATZ and nutrients, as well as the enzyme activity and the distribution of functional genes in vertical subsurface-flow CW microcosm. The results showed that compared to the control group (CK), CWs treated with different concentrations of MPs had no significant difference in the removal of ATZ. Moreover, in the second stage (ATZ=400 μg/L), the average removal efficiency of ATZ by CWs containing MPs was slightly higher than that of the CK group. PE MPs reduced the nitrogen removal efficiency of CWs by 1.57 %-3.03 %, but had no significant effect on TP removal. The concentration distribution of PE MPs in the substrate layer exhibited a decreasing trend from top to bottom, and the interception capacity of CWs gradually decreased with time (from 100 % to 97.4 %); When exposed to PE MPs, the activities of enzymes in substrate related to nitrogen metabolism were inhibited; Moreover, the addition of PE MPs in CWs promoted the removal of ATZ by increasing the abundance of ATZ metabolizing bacteria (Hydrogenophaga, Zoogloea, Rhizobium, etc.) and ATZ degradation key genes (atzA and trzN). These results not only provide theoretical support for the practical application of CWs in the treatment of pesticide wastewater, but also provide a theoretical basis for the environmental risk control of pesticide non-point source pollution ecological treatment technology in the presence of MPs.

2025-08-01·JOURNAL OF HAZARDOUS MATERIALS

Atrazine disrupts nitrogen removal performance and greenhouse gas abatement in bioretention systems: Unraveling microbiotas and macrophytes responses

Article

作者: Lian, Xiaoke ; Tang, Yinghui ; Hou, Yizhi ; Chen, Yao ; Wang, Kaifeng ; Yuan, Ying ; Xiao, Wenyu ; Chen, Quanhong ; Cheng, Qiming ; Liu, Zhen ; Zou, Gaoju

The potential impact of stormwater runoff-induced loss of triazine herbicides, like atrazine (ATZ), on soil nitrogen cycling remains poorly understood. Bioretention systems (BRS) represent effective stormwater control measures (SCM) now understood to serve as important ATZ accumulation zones. However, the effects of ATZ exposure on nitrogen removal and greenhouse gas (GHG) abatement within BRS remain unclear. In the present study, bioretention columns were established and exposed to ATZ (0-25 mg kg^-1) for 200 days. The results demonstrated that the accumulation of ATZ led to a reduction in total nitrogen removal efficiency (by 7.7-49.3 %) while simultaneously causing an increase in GHG emission fluxes (by 11.2 %-25.1 %). Moreover, ATZ significantly altered microbial activities, including nitrogen metabolism enzymes (hydroxylamine oxidoreductase, nitrate reductase, and nitrite reductase) and the electron transport system (ETSA). Microbial community analysis showed that ATZ reduced the relative abundance of nitrifying bacteria (Nitrospira and Nitrosomonas), along with certain denitrifying bacteria (Thauera, Terrimonas, and Dechloromona). Besides, the compromised function of leaves and roots diminished plant nitrogen uptake, and the application of structural equation modeling (SEM) revealed an increased contribution of plants to nitrogen removal. These findings collectively suggest that the widespread presence of triazine herbicides in urban areas could potentially impact the performance of SCMs.

2,232

项与阿替利珠单抗相关的新闻（医药）

2025-06-05

·美通社

再获BTD：信达生物IBI363（PD-1/IL-2α-bias双特异性抗体融合蛋白）获国家药品监督管理局纳入突破性治疗药物品种，治疗免疫耐药鳞状非小细胞肺癌

美国旧金山和中国苏州 2025年6月5日 /美通社/ -- 信达生物制药集团（香港联交所股票代码：01801），一家致力于研发、生产和销售肿瘤、自身免疫、代谢、眼科等重大疾病领域创新药物的生物制药公司，宣布其全球首创PD-1/IL-2 α-bias 双特异性抗体融合蛋白IBI363已被中国国家药品监督管理局（NMPA）药品审评中心（CDE）纳入突破性治疗药物（ BTD）品种名单，拟定适应症为经含铂化疗及抗PD - 1/PD - L1免疫治疗失败的局部晚期或转移性鳞状非小细胞肺癌。截至目前， IBI363在鳞状非小细胞肺癌和黑色素瘤的两项适应症已经分别获得中国CDE的BTD认证和美国FDA快速通道资格（FTD）认定，此次BTD标志着IBI363在解决免疫耐药及冷肿瘤治疗难题中再前进一步。 IBI363在既往接受过免疫治疗的鳞状非小细胞肺癌受试者的临床I期研究最新数据在2025年ASCO大会上以口头形式报告。在免疫治疗耐药的鳞状非小细胞肺癌和野生型肺腺癌中，都观察到了可控的安全性、令人鼓舞的疗效和长期生存获益，有望为免疫耐药患者提供新的治疗希望。在今年ASCO会议上，IBI363口头报告了在免疫耐药非小细胞肺癌、结直肠癌、黑色素瘤三项免疫耐药及冷肿瘤中的突破性临床研究结果，并获得广泛关注。信达生物制药集团高级副总裁周辉博士表示："IBI363引领着下一代免疫治疗的进化方向——通过‘PD-1靶向+IL-2激活扩增肿瘤特异性T细胞'的免疫检查点阻断+细胞因子激动双重作用，重塑肿瘤免疫微环境。IBI363在近期接连获得多项FTD和BTD，标志着监管机构认可其针对未满足需求的临床价值。我们正在加速推进IBI363的多瘤种的全球开发，其中头对头帕博利珠单抗的首个注册临床研究在粘膜及肢端型黑色素瘤已启动，公司还将与监管沟通IBI363在肺癌和结直肠癌的注册临床研究方案，以创新疗法开启肿瘤免疫治疗新篇章。" 突破性治疗药物资格认定是为了加快开发针对严重疾病、且已在初步临床试验中显示疗效或安全性方面显著优于现有治疗手段的新药而设计的。获得突破性治疗药物认定能够使该药在研发过程中与 CDE密切交流、获得指导，从而加快新药上市，更早解决中国病患未满足的临床需求。关于鳞状非小细胞肺癌肺癌是全球及中国发病率和死亡率最高的恶性肿瘤 [1] ，是危害公共健康的重大问题。尽管免疫治疗已经彻底改变了非小细胞肺癌的治疗格局，但对于免疫治疗失败且无驱动基因突变的非小细胞肺癌患者，目前仍缺乏有效的治疗手段。标准治疗方案多西他赛疗效有限，ORR不到20%，PFS不到4个月，OS不到12个月 [2-7] 。近年来，虽然免疫联合治疗、抗体偶联药物（Antibody-drug conjugates，ADCs）等新型治疗方案的探索带来了新的希望，但多项针对含铂化疗及免疫治疗失败的非小细胞肺癌人群的大型III期临床研究均未获得令人满意的结果，其中多数研究未达到主要终点 [2-6] 。TROPION-Lung01研究虽然在NSCLC中达到PFS主要终点（未达到OS主要终点），但在鳞状非小细胞肺癌中，试验组的PFS/OS/ORR均未见提升 [7] 。因此，在免疫治疗失败的鳞状非小细胞肺癌中，存在巨大且迫切的未满足的临床需求。关于 IBI363（PD-1/IL-2 α-bias 双特异性融合蛋白） IBI363是由信达生物自主研发的全球首创PD-1/IL-2 α -bias 双特异性融合蛋白，同时具有阻断PD-1/PD-L1通路和激活IL-2通路两项功能。IBI363的IL-2臂经过了设计改造，保留了其对IL-2 Rα的亲和力，但削弱了对IL-2Rβ和IL-2Rγ的结合能力，以此降低毒性；而PD-1结合臂可以同时实现对PD-1的阻断和IL-2的选择性递送。由于新激活的肿瘤特异性T细胞同时表达PD-1和IL-2α，这一差异性策略可以更精确和有效地实现对该 T细胞亚群的靶向和激活。IBI363不仅在多种荷瘤药理学模型中展现出了良好抗肿瘤活性，在PD-1耐药和转移模型中也表现出了突出的抑瘤效力。在今年ASCO会议上，IBI363口头报告了在免疫耐药非小细胞肺癌、结直肠癌、黑色素瘤三项免疫耐药及冷肿瘤中的突破性临床研究结果，并获得广泛关注。从临床迫切需求出发，信达生物正在中国、美国、澳大利亚开展临床研究探索IBI363在针对各种恶性肿瘤的有效性和安全性。IBI363已开出首个关键注册临床研究，用于治疗未经免疫治疗的粘膜型和肢端型黑色素瘤。 IBI363已获美国FDA两项快速通道资格认定，分别用于治疗晚期鳞状非小细胞肺癌和黑色素瘤。IBI363也获得中国NMPA纳入两项突破性疗法认证，治疗晚期黑色素瘤和鳞状非小细胞肺癌。关于信达生物 "始于信，达于行"，开发出老百姓用得起的高质量生物药，是信达生物的使命和目标。信达生物成立于2011年，致力于研发、生产和销售肿瘤、自身免疫、代谢、眼科等重大疾病领域的创新药物，让我们的工作惠及更多的生命。公司已有15个产品获得批准上市，它们分别是信迪利单抗注射液（达伯舒®），贝伐珠单抗注射液（达攸同®），阿达木单抗注射液（苏立信®），利妥昔单抗注射液（达伯华®），佩米替尼片（达伯坦®），奥雷巴替尼片（耐立克®），雷莫西尤单抗注射液（希冉择®），塞普替尼胶囊（睿妥®），伊基奥仑赛注射液（福可苏®），托莱西单抗注射液（信必乐®）, 氟泽雷塞片（达伯特®），匹妥布替尼片（捷帕力®），己二酸他雷替尼胶囊（达伯乐®）和利厄替尼片（奥壹新®）和替妥尤单抗N01注射液（信必敏®）。目前，同时还有3个品种在NMPA审评中，4个新药分子进入III期或关键性临床研究，另外还有15个新药品种已进入临床研究。公司已与礼来、罗氏、赛诺菲、Incyte和MD Anderson 癌症中心等国际合作方达成30多项战略合作。信达生物在不断自研创新药物、谋求自身发展的同时，秉承经济建设以人民为中心的发展思想。多年来，始终心怀科学善念，坚守"以患者为中心"，心系患者并关注患者家庭，积极履行社会责任。公司陆续发起、参与了多项药品公益援助项目，让越来越多的患者能够得益于生命科学的进步，买得到、用得起高质量的生物药。截至目前，信达生物患者援助项目已惠及20余万普通患者，药物捐赠总价值36亿元人民币。信达生物希望和大家一起努力，提高中国生物制药产业的发展水平，以满足百姓用药可及性和人民对生命健康美好愿望的追求。详情请访问公司网站： www.innoventbio.com 或公司领英账号 www.linkedin.com/company/innovent-biologics/ 。声明： 1. 信达生物不推荐未获批的药品 / 适应症的使用。 2. 雷莫西尤单抗注射液（希冉择 ® ）塞普替尼胶囊（睿妥 ® ）和匹妥布替尼片（捷帕力 ® ）由礼来公司研发前瞻性声明本新闻稿所发布的信息中可能会包含某些前瞻性表述。这些表述本质上具有相当风险和不确定性。在使用"预期"、"相信"、"预测"、"期望"、"打算"及其他类似词语进行表述时，凡与本公司有关的，目的均是要指明其属前瞻性表述。本公司并无义务不断地更新这些预测性陈述。这些前瞻性表述乃基于本公司管理层在做出表述时对未来事务的现有看法、假设、期望、估计、预测和理解。这些表述并非对未来发展的保证，会受到风险、不确性及其他因素的影响，有些乃超出本公司的控制范围，难以预计。因此，受我们的业务、竞争环境、政治、经济、法律和社会情况的未来变化及发展的影响，实际结果可能会与前瞻性表述所含资料有较大差别。本公司、本公司董事及雇员代理概不承担 (a) 更正或更新本网站所载前瞻性表述的任何义务;及 (b) 若因任何前瞻性表述不能实现或变成不正确而引致的任何责任。参考文献 [1] Globocan 2022 (version 1.1) - 08.02.2024 [2] Paz-Ares LG, Juan-Vidal O, Mountzios GS, et al. Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study. J Clin Oncol. Aug 20 2024;42(24):2860-2872. doi:10.1200/JCO.24.00733 [3] Neal J, Pavlakis N, Kim SW, et al. CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy. J Clin Oncol. Jul 10 2024;42(20):2393-2403. doi:10.1200/JCO.23.02166 [4] SAFFRON-301: Tislelizumab plus sitravatinib in advanced/metastatic NSCLC progressing on/after chemotherapy and anti–PD-(L)1. WCLC 2024. [5] 65O - Phase 3 LEAP-008 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic non-small cell lung cancer (NSCLC) that progressed on a PD-(L)1 inhibitor and platinum-containing chemotherapy. ESMO IO 2023. [6] Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial. Lung Cancer . 2024 Mar:189:107451. doi: 10.1016/j.lungcan.2023.107451. Epub 2024 Jan 16. [7] Ahn MJ, Tanaka K, Paz-Ares L, et al. Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study. J Clin Oncol. Sep 9 2024:JCO2401544. doi:10.1200/JCO-24-01544

突破性疗法ASCO会议免疫疗法临床1期临床结果

2025-06-05

·信达生物

再获BTD：IBI363（PD-1/IL-2α-bias双抗融合蛋白）被纳入突破性治疗药物品种，治疗免疫耐药鳞状非小细胞肺癌

2025年6月5日，美国旧金山和中国苏州——信达生物制药集团（香港联交所股票代码：01801），一家致力于研发、生产和销售肿瘤、自身免疫、代谢、眼科等重大疾病领域创新药物的生物制药公司，宣布其全球首创PD-1/IL-2α-bias双特异性抗体融合蛋白IBI363已被中国国家药品监督管理局（NMPA）药品审评中心（CDE）纳入突破性治疗药物（BTD）品种名单，拟定适应症为经含铂化疗及抗PD - 1/PD - L1免疫治疗失败的局部晚期或转移性鳞状非小细胞肺癌。截至目前，IBI363在鳞状非小细胞肺癌和黑色素瘤的两项适应症已经分别获得中国CDE的BTD认证和美国FDA快速通道资格（FTD）认定，此次BTD标志着IBI363在解决免疫耐药及冷肿瘤治疗难题中再前进一步。IBI363在既往接受过免疫治疗的鳞状非小细胞肺癌受试者的临床I期研究最新数据在2025年ASCO大会上以口头形式报告。在免疫治疗耐药的鳞状非小细胞肺癌和野生型肺腺癌中，都观察到了可控的安全性、令人鼓舞的疗效和长期生存获益，有望为免疫耐药患者提供新的治疗希望。在今年ASCO会议上，IBI363口头报告了在免疫耐药非小细胞肺癌、结直肠癌、黑色素瘤三项免疫耐药及冷肿瘤中的突破性临床研究结果，并获得广泛关注。信达生物制药集团高级副总裁周辉博士表示：“IBI363引领着下一代免疫治疗的进化方向——通过‘PD-1靶向+IL-2激活扩增肿瘤特异性T细胞’的免疫检查点阻断+细胞因子激动双重作用，提升T细胞功能的同时扩增T细胞数量，重塑肿瘤免疫微环境。IBI363在近期接连获得多项FTD和BTD，标志着监管机构认可其针对未满足需求的临床价值。我们正在加速推进IBI363的多瘤种的全球开发，其中头对头帕博利珠单抗的首个注册临床研究在粘膜及肢端型黑色素瘤已启动，公司还将与监管沟通IBI363在肺癌和结直肠癌的注册临床研究方案，以创新疗法开启肿瘤免疫治疗新篇章。”突破性治疗药物资格认定是为了加快开发针对严重疾病、且已在初步临床试验中显示疗效或安全性方面显著优于现有治疗手段的新药而设计的。获得突破性治疗药物认定能够使该药在研发过程中与CDE密切交流、获得指导，从而加快新药上市，更早解决中国病患未满足的临床需求。关于鳞状非小细胞肺癌- 滑动查看更多介绍 -肺癌是全球及中国发病率和死亡率最高的恶性肿瘤1，是危害公共健康的重大问题。尽管免疫治疗已经彻底改变了非小细胞肺癌的治疗格局，但对于免疫治疗失败且无驱动基因突变的非小细胞肺癌患者，目前仍缺乏有效的治疗手段。标准治疗方案多西他赛疗效有限，ORR不到20%，PFS不到4个月，OS不到12个月2-7。近年来，虽然免疫联合治疗、抗体偶联药物（Antibody-drug conjugates，ADCs）等新型治疗方案的探索带来了新的希望，但多项针对含铂化疗及免疫治疗失败的非小细胞肺癌人群的大型III期临床研究均未获得令人满意的结果，其中多数研究未达到主要终点2-6。TROPION-Lung01研究虽然在NSCLC中达到PFS主要终点（未达到OS主要终点），但在鳞状非小细胞肺癌中，试验组的PFS/OS/ORR均未见提升7。因此，在免疫治疗失败的鳞状非小细胞肺癌中，存在巨大且迫切的未满足的临床需求。关于IBI363（PD-1/IL-2α-bias双特异性融合蛋白）- 滑动查看更多介绍 -IBI363是由信达生物自主研发的全球首创PD-1/IL-2α-bias双特异性融合蛋白，同时具有阻断PD-1/PD-L1通路和激活IL-2通路两项功能。IBI363的IL-2臂经过了设计改造，保留了其对IL-2 Rα的亲和力，但削弱了对IL-2Rβ和IL-2Rγ的结合能力，以此降低毒性；而PD-1结合臂可以同时实现对PD-1的阻断和IL-2的选择性递送。由于新激活的肿瘤特异性T细胞同时表达PD-1和IL-2α，这一差异性策略可以更精确和有效地实现对该T细胞亚群的靶向和激活。IBI363不仅在多种荷瘤药理学模型中展现出了良好抗肿瘤活性，在PD-1耐药和转移模型中也表现出了突出的抑瘤效力。在今年ASCO会议上，IBI363口头报告了在免疫耐药非小细胞肺癌、结直肠癌、黑色素瘤三项免疫耐药及冷肿瘤中的突破性临床研究结果，并获得广泛关注。从临床迫切需求出发，信达生物正在中国、美国、澳大利亚开展临床研究探索IBI363在针对各种恶性肿瘤的有效性和安全性。IBI363已开出首个关键注册临床研究，用于治疗未经免疫治疗的粘膜型和肢端型黑色素瘤。IBI363已获美国FDA两项快速通道资格认定，分别用于治疗晚期鳞状非小细胞肺癌和黑色素瘤。IBI363也获得中国NMPA纳入两项突破性疗法认证，治疗晚期黑色素瘤和鳞状非小细胞肺癌。关于信达生物- 滑动查看更多介绍 -“始于信，达于行”，开发出老百姓用得起的高质量生物药，是信达生物的使命和目标。信达生物成立于2011年，致力于研发、生产和销售肿瘤、自身免疫、代谢、眼科等重大疾病领域的创新药物，让我们的工作惠及更多的生命。公司已有15个产品获得批准上市，它们分别是信迪利单抗注射液（达伯舒®），贝伐珠单抗注射液（达攸同®），阿达木单抗注射液（苏立信®），利妥昔单抗注射液（达伯华®），佩米替尼片（达伯坦®），奥雷巴替尼片（耐立克®），雷莫西尤单抗注射液（希冉择®），塞普替尼胶囊（睿妥®），伊基奥仑赛注射液（福可苏®），托莱西单抗注射液（信必乐®），氟泽雷塞片（达伯特®），匹妥布替尼片(捷帕力®)，己二酸他雷替尼胶囊（达伯乐®），利厄替尼片（奥壹新®）和替妥尤单抗N01注射液（信必敏®）。目前，同时还有3个品种在NMPA审评中，4个新药分子进入III期或关键性临床研究，另外还有15个新药品种已进入临床研究。公司已与礼来、罗氏、赛诺菲、Incyte和MD Anderson 癌症中心等国际合作方达成30多项战略合作。信达生物在不断自研创新药物、谋求自身发展的同时，秉承经济建设以人民为中心的发展思想。多年来，始终心怀科学善念，坚守“以患者为中心”，心系患者并关注患者家庭，积极履行社会责任。公司陆续发起、参与了多项药品公益援助项目，让越来越多的患者能够得益于生命科学的进步，买得到、用得起高质量的生物药。截至目前，信达生物患者援助项目已惠及20余万普通患者，药物捐赠总价值36亿元人民币。信达生物希望和大家一起努力，提高中国生物制药产业的发展水平，以满足百姓用药可及性和人民对生命健康美好愿望的追求。详情请访问公司网站：www.innoventbio.com或公司领英账号：Innovent Biologics。声明：1.信达不推荐任何未获批的药品/适应症使用。2.雷莫西尤单抗注射液（希冉择®），塞普替尼胶囊（睿妥®）和匹妥布替尼片（捷帕力®）由礼来公司研发。前瞻性声明本新闻稿所发布的信息中可能会包含某些前瞻性表述。这些表述本质上具有相当风险和不确定性。在使用“预期”、“相信”、“预测”、“期望”、“打算”及其他类似词语进行表述时，凡与本公司有关的，均属于前瞻性表述。本公司并无义务不断地更新这些预测性陈述。这些前瞻性表述是基于本公司管理层在做出表述时对未来事务的现有看法、假设、期望、估计、预测和理解。这些表述并非对未来发展的保证，会受到风险、不确性及其他因素的影响，有些是超出本公司的控制范围，难以预计。因此，受我们的业务、竞争环境、政治、经济、法律和社会情况的未来变化及发展的影响，实际结果可能会与前瞻性表述所含资料有较大差别。本公司、本公司董事及雇员代理概不承担 (a) 更正或更新本网站所载前瞻性表述的任何义务;及 (b) 若因任何前瞻性表述不能实现或变成不正确而引致的任何责任。参考文献：[1] Globocan 2022 (version 1.1) - 08.02.2024[2] Paz-Ares LG, Juan-Vidal O, Mountzios GS, et al. Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study. J Clin Oncol. Aug 20 2024;42(24):2860-2872. doi:10.1200/JCO.24.00733[3] Neal J, Pavlakis N, Kim SW, et al. CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy. J Clin Oncol. Jul 10 2024;42(20):2393-2403. doi:10.1200/JCO.23.02166[4] SAFFRON-301: Tislelizumab plus sitravatinib in advanced/metastatic NSCLC progressing on/after chemotherapy and anti–PD-(L)1. WCLC 2024.[5] 65O - Phase 3 LEAP-008 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic non-small cell lung cancer (NSCLC) that progressed on a PD-(L)1 inhibitor and platinum-containing chemotherapy. ESMO IO 2023.[6] Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial. Lung Cancer . 2024 Mar:189:107451. doi: 10.1016/j.lungcan.2023.107451. Epub 2024 Jan 16.[7] Ahn MJ, Tanaka K, Paz-Ares L, et al. Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study. J Clin Oncol. Sep 9 2024:JCO2401544. doi:10.1200/JCO-24-01544

突破性疗法ASCO会议免疫疗法临床结果临床1期

2025-06-04

·罗氏制药

罗氏2025 ASCO聚焦：多瘤种肿瘤产品组合新数据亮相

在刚刚结束的第61届美国临床肿瘤学会（ASCO）年会上，罗氏公布了多项肿瘤领域的最新研究进展，重点展示了乳腺癌领域、肺癌领域和血液肿瘤领域的肿瘤产品组合新数据。这些关键研究结果，进一步突显了罗氏致力于为癌症患者开发变革性疗法的承诺。III期INAVO120研究显示，在内分泌耐药、PIK3CA突变HR+/HER2-局部晚期或转移性乳腺癌患者一线治疗中，伊那利塞（inavolisib）联合哌柏西利+氟维司群治疗组的中位OS长达34个月，较安慰剂联合对照组的27个月显著延长7个月。● 与哌柏西利（palbociclib）和氟维司群（fulvestrant）相比，基于Itovebi™ (inavolisib)的治疗方案将内分泌耐药、PIK3CA突变的HR阳性、HER2阴性晚期乳腺癌患者的死亡风险降低了30%以上[1]● 最新数据在2025年美国临床肿瘤学会（ASCO）年会的口头报告环节呈报，同期并发表于《新英格兰医学杂志》[1]PIK3CA突变存在于约40%的HR阳性晚期乳腺癌中，且与不良预后相关[2,3]。除INAVO120研究外，Itovebi目前还在三项公司申办的III期研究（INAVO121, INAVO122，INAVO123）中进行评估，这些研究均针对PIK3CA突变的局部晚期或转移性乳腺癌，采用不同的联合治疗方案。[4-7]罗氏正在乳腺癌和其他肿瘤类型中展开更多探索，希望能将这种靶向治疗的益处带给更多携带PIK3CA突变的患者。III期IMforte研究取得积极结果：Tecentriq联合Lurbinectedin治疗广泛期小细胞肺癌显示显著生存获益● 在该侵袭性强、生存期有限且治疗选择稀缺的癌症类型中，疾病进展或死亡风险降低46%，死亡风险降低27%[8]● 首个在广泛期小细胞肺癌（ES-SCLC）一线维持治疗中，证实无进展生存期和总生存期均取得临床意义改善的III期研究[9,10]● 研究数据已在2025年ASCO年会口头报告环节公布，并同步发表于《柳叶刀》[8,11]III期STARGLO研究随访两年的更新数据证实：Glofit-GemOx方案可延长复发或难治性弥漫性大B细胞淋巴瘤患者的总生存期● 对于不适合移植的复发/难治性弥漫性大B细胞淋巴瘤（R/R DLBCL）患者，总生存期持续显示出具有临床意义的改善，中位OS尚未达到，疾病死亡风险降低40%[12]● 更新的Landmark分析数据显示，在Glofit-GemOx方案治疗结束时获得完全缓解的患者中，82%未发生疾病进展[12]● 同时，完全缓解率达58.5%，且患者可持续获得完全缓解状态，目前随访两年数据显示DoCR仍未达到[12]所以，对于这种侵袭性、危及生命的疾病，在复发或初始治疗失败后及时启动有效治疗至关重要！Glofit-GemOx方案作为一种亟需的、固定疗程、“即用型”TCE疗法具有巨大潜力。“我们将集中端到端的资源，聚焦乳腺癌、肺癌和恶性血液肿瘤——这些存在大量未被满足临床需求的疾病领域，而我们在这方面已积淀深厚专业优势。在三大重点疾病领域之外，我们还将持续探索其他具有变革性治疗潜力的癌症类型，寻求突破性的创新。”参考文献：[1] Turner NC, et al. INAVO120 Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC). Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, 2025 May 30-June 03; Chicago, USA. Abstract #1003.[2] Fillbrunn M, et al. PIK3CA mutation status, progression and survival in advanced HR+/HER2- breast cancer: a meta-analysis of published clinical trials. BMC Cancer. 2022;22(1):1002.[3] Anderson E, et al. A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2– Metastatic Breast Cancer. Int J Breast Cancer. 2020;2020:3759179.[4] ClinicalTrials.gov. A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer (INAVO120) [Internet; cited 2025 May]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04191499.[5] ClinicalTrials.gov. A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy (INAVO121) [Internet; cited 2025 May]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05646862. [6] ClinicalTrials.gov. A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer (INAVO122) [Internet; cited 2025 May]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05894239. [7] ClinicalTrials.gov. A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer (INAVO123) [Internet; cited 2025 May]. Available from: https://clinicaltrials.gov/study/NCT06790693.[8] Paz-Ares L, et al. Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial. Presented at: ASCO Annual Meeting; 2025 May 30-Jun 03; Chicago, IL, USA. Abstract #8006.[9] Belluomini L, et al. Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysis. Seminars in Oncology. 2022; 49(5): 389-393. [10] Roviello G, et al. No advantage in survival with targeted therapies as maintenance in patients with limited and extensive-stage small cell lung cancer: a literature-based meta-analysis of randomized trials. Clin Lung Cancer. 2016; 17(5): 334–340.[11] Paz-Ares L, et al. Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2025 Jun 02. [Internet; cited June 2025]. Available from: https://doi-org.libproxy1.nus.edu.sg/10.1016/S0140-6736(25)01011-6.[12] Abramson J, et al. Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year (yr) follow-up of STARGLO. Presented at: ASCO Annual Meeting; 2025 May 30 - Jun 3. Abstract #7015.1.本新闻稿旨在分享研发前沿资讯，仅供中国境内医疗卫生专业人士参阅，非广告用途。2.罗氏不推荐任何未被批准的药品、适应症的使用。更多新闻罗氏宣布肝癌III期临床研究TALENTACE达到主要研究终点《新英格兰医学杂志》：研究证实速福达®(玛巴洛沙韦)可显著降低流感病毒传播

ASCO会议临床结果临床3期

100 项与阿替利珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10773	阿替利珠单抗	L01XC32	DB11595

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
晚期非小细胞肺癌	欧盟	Roche Registration GmbH	2024-07-25
晚期非小细胞肺癌	冰岛	Roche Registration GmbH	2024-07-25
晚期非小细胞肺癌	列支敦士登	Roche Registration GmbH	2024-07-25
晚期非小细胞肺癌	挪威	Roche Registration GmbH	2024-07-25
乳腺癌	加拿大	F. Hoffmann-La Roche Ltd.	2024-03-13
肺泡软组织肉瘤	美国	Genentech, Inc.	2022-12-09
PD-L1阳性非小细胞肺癌	日本	Chugai Pharmaceutical Co., Ltd.	2022-05-26
BRAF V600 突变阳性黑色素瘤	美国	Genentech, Inc.	2020-07-30
PD-L1阳性三阴性乳腺癌	日本	Chugai Pharmaceutical Co., Ltd.	2018-01-19
晚期肝细胞癌	欧盟	Roche Registration GmbH	2017-09-20
晚期肝细胞癌	冰岛	Roche Registration GmbH	2017-09-20
晚期肝细胞癌	列支敦士登	Roche Registration GmbH	2017-09-20
晚期肝细胞癌	挪威	Roche Registration GmbH	2017-09-20
晚期三阴性乳腺癌	欧盟	Roche Registration GmbH	2017-09-20
晚期三阴性乳腺癌	冰岛	Roche Registration GmbH	2017-09-20
晚期三阴性乳腺癌	列支敦士登	Roche Registration GmbH	2017-09-20
晚期三阴性乳腺癌	挪威	Roche Registration GmbH	2017-09-20
广泛期小细胞肺癌	欧盟	Roche Registration GmbH	2017-09-20
广泛期小细胞肺癌	冰岛	Roche Registration GmbH	2017-09-20
广泛期小细胞肺癌	列支敦士登	Roche Registration GmbH	2017-09-20

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
结外NK-T细胞淋巴瘤	申请上市	日本	Chugai Pharmaceutical Co., Ltd.	2024-10-31
1型糖尿病	申请上市	中国	Provention Bio, Inc.	2024-08-28
膀胱癌	申请上市	中国	Roche Holding AG	2019-02-25
淋巴组织增生性疾病	临床3期	英国	-	2023-10-25
黑色素瘤	临床3期	英国	-	2023-10-25
MSI-H 癌症	临床3期	英国	-	2023-10-25
Turcot综合征	临床3期	英国	-	2023-10-25
肌层浸润性膀胱癌	临床3期	比利时	Hoffmann-La Roche, Inc.	2021-05-03
肌层浸润性膀胱癌	临床3期	中国香港	Hoffmann-La Roche, Inc.	2021-05-03
肌层浸润性膀胱癌	临床3期	墨西哥	Hoffmann-La Roche, Inc.	2021-05-03

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03554083 (NeoACTIVATE arm C, ASCO2025)	临床2期	新辅助 \| 辅助 TIGIT	34	Atezolizumab 1200mg IV + Tiragolumab 600mg IV	鏇艱憲糧蓋獵艱鬱積簾(齋顧膚繭糧簾憲積餘醖) = 5 patients (14.7%) experienced any grade 3+ AE with 2 (5.9%) at least possibly related to the neoadjuvant regimen 齋鏇遞齋範鑰鏇憲窪願 (獵醖構壓範窪觸簾衊獵 )	积极	2025-05-30
ASCO2025	N/A	晚期肝细胞癌二线	552	Lenvatinib	構蓋選窪顧製淵艱窪製(糧鹹鏇選網襯齋衊膚淵) = 鹹鑰齋鑰鬱齋膚膚顧遞衊網鑰網顧顧餘蓋膚餘 (壓願遞蓋鏇艱夢憲窪糧 )	不佳	2025-05-30
				Cabozantinib	構蓋選窪顧製淵艱窪製(糧鹹鏇選網襯齋衊膚淵) = 淵衊繭憲壓醖觸鑰觸淵衊網鑰網顧顧餘蓋膚餘 (壓願遞蓋鏇艱夢憲窪糧 )
NCT04338269 (CONTACT-03, ASCO2025)	临床3期	晚期肾细胞癌二线	522	Cabozantinib (cabo)	壓築簾積壓壓顧簾夢遞(鏇鹽醖獵艱獵鏇醖膚鏇) = 鬱鏇艱製窪蓋顧築積襯積築網衊積觸糧繭構網 (餘顧鏇鹹構構遞獵膚憲 ) 更多	积极	2025-05-30
				Cabozantinib (cabo) + Atezolizumab (atezo)	壓築簾積壓壓顧簾夢遞(鏇鹽醖獵艱獵鏇醖膚鏇) = 積窪齋夢製製鏇廠繭繭積築網衊積觸糧繭構網 (餘顧鏇鹹構構遞獵膚憲 ) 更多
ASCO2025	N/A	不可切除的肝细胞癌一线 Non-Alcoholic Steatohepatitis (NASH)	21	Atezolizumab and Bevacizumab Combination	遞遞築構繭選顧鹽獵遞(鹹鏇窪憲憲鏇憲艱構窪) = 57.1% 糧蓋淵構製網鏇製願衊 (糧窪鹹築鹽壓憲觸積顧 ) 更多	不佳	2025-05-30
NCT03108131 (CTgov)	临床2期	腺癌 \| 肝转移 \| 肿瘤转移 ... 更多	49	Cobimetinib+atezolizumab+5FU	顧醖製範網憲鏇鬱構構 = 餘壓網獵窪範衊構構艱蓋醖壓製糧積膚夢鑰製 (觸齋鹽積獵選餘鹽鬱顧, 鑰範繭網顧膚簾網襯鹽 ~ 糧願廠蓋鏇膚願選夢範) 更多	-	2025-05-28
NCT04642365 (CTgov)	临床1期	晚期恶性实体瘤	49	Atezolizumab+RO7296682 (Part 1: Cohort 1 - RO7296682 0.3 mg + Atezolizumab 1200 mg)	夢鹽壓醖範繭範製網淵 = 築鏇觸夢餘艱艱醖網鏇窪糧鹹願鏇構積願糧觸 (齋壓積齋顧鬱蓋鹽網糧, 選鹽選夢淵鹹鑰鹽網繭 ~ 艱簾製範選鏇夢選壓艱) 更多	-	2025-05-21
				Atezolizumab+RO7296682 (Part 1: Cohort 2 - RO7296682 1.5 mg + Atezolizumab 1200 mg)	夢鹽壓醖範繭範製網淵 = 廠餘繭繭窪鹹願膚憲鹹窪糧鹹願鏇構積願糧觸 (齋壓積齋顧鬱蓋鹽網糧, 選鏇網廠鬱衊觸鹽鏇憲 ~ 遞獵膚鹹鹹憲窪廠鏇獵) 更多
NCT04730999 (CeLEBrATE, NEWS) 人工标引	临床2期	广泛期小细胞肺癌一线	48	阿替利珠单抗+贝伐单抗+卡铂+依托泊苷	範觸窪簾選願積構積遞(製鑰遞獵顧餘獵範鏇艱) = 艱餘鏇憲淵鏇餘餘獵鬱廠繭廠構餘憲壓齋憲簾 (憲膚選構鑰範鏇膚鏇壓 ) 更多	积极	2025-05-20
NCT02366143 (IMpower151, Pubmed) 人工标引	临床3期	转移性非鳞状非小细胞肺癌一线	305	Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel or pemetrexed	膚壓齋繭餘繭積鹽鹽蓋(構衊蓋廠鹽膚廠築襯製) = 鏇鬱壓襯艱觸鏇艱鬱艱壓鹽餘構構鬱遞窪選顧 (鹽製積鏇糧顧憲憲淵鹽 ) 更多	不佳	2025-05-16
				Placebo + Bevacizumab + Carboplatin + Pemetrexed or Paclitaxel or paclitaxel	膚壓齋繭餘繭積鹽鹽蓋(構衊蓋廠鹽膚廠築襯製) = 鬱艱淵鑰築糧襯繭窪憲壓鹽餘構構鬱遞窪選顧 (鹽製積鏇糧顧憲憲淵鹽 ) 更多
NCT04148911 (EL1SSAR, ESMO_BC2025)	临床3期	PD-L1阳性三阴性乳腺癌一线 PD-L1+	182	Atezolizumab + nab-paclitaxel	遞獵積襯蓋積膚網遞衊(廠醖醖壓壓積簾齋鏇鹽) = 膚簾願餘窪壓壓膚鏇餘艱壓觸膚襯繭鏇衊遞積 (膚顧衊壓鑰獵衊齋遞醖, 39 ~ 54) 更多	积极	2025-05-15
NCT04732286 (CTgov)	临床3期	肝细胞癌	100	Atezolizumab+Bevacizumab (Atezolizumab + Bevacizumab)	範夢鏇鹽齋衊鏇鏇遞鑰 = 簾膚範齋餘齋壓蓋觸襯構醖膚鹽壓鑰鏇觸簾鏇 (願鹽壓選壓淵廠選膚廠, 廠憲窪築醖憲醖願蓋艱 ~ 鏇鏇窪製製膚淵壓鹽夢) 更多	-	2025-05-08
				Atezolizumab+Bevacizumab (Atezolizumab + Bevacizumab:)	蓋壓選蓋艱簾鏇鬱觸壓(網顧積範襯齋構壓鹽範) = 簾壓鬱繭齋製製觸衊蓋廠鬱鏇夢壓簾簾憲淵築 (廠餘憲廠範積鏇醖壓鬱, 窪觸鹽獵鹹築糧襯襯鑰 ~ 選顧醖鬱顧夢觸餘廠簾) 更多